# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Biotres Pro Is Also Capturing The Attention Of New Customers. The Initial Production Run Of Biotres Pro Has Sold Out, With Cust...
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new d...